Economic Burden of COPD by Disease Severity – A Nationwide Cohort Study in Denmark

References

• ERS - Respiratory health and disease in Europe. Available from: https://www.erswhitebook.org/. Accessed June 21, 2020.
   Google Scholar
• Forum of International Respiratory Societies. The Global Impact of Respiratory Disease. 2nd ed. Sheffield: European Respiratory Society, Forum of International Respiratory Societies; 2017.
   Google Scholar
• Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clin Outcomes Res. 2013;5:235–245.
   PubMedGoogle Scholar
• Løkke A, Fabricius PG, Vestbo J, Marott JL, Lange P. Prevalence of chronic obstructive pulmonary disease in Copenhagen. Results from the Copenhagen city heart study. Ugeskr Læger. 2007;169(46):3956–3960.
   PubMedGoogle Scholar
• Bilde L, Rud Svenning A, Dollerup J, Bække Borgeskov H, Lange P. The cost of treating patients with COPD in Denmark - A population study of COPD patients compared with non-COPD controls. Respir Med. 2007;101:539–546. doi:10.1016/j.rmed.2006.06.020
   PubMed Web of Science ®Google Scholar
• Løkke A, Hilberg O, Tønnesen P, et al. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998–2010. BMJ Open. 2014;4:e004069. doi:10.1136/bmjopen-2013-004069
   PubMed Web of Science ®Google Scholar
• Løkke A, Hilberg O, Kjellberg J, Ibsen R, Jennum P. Economic and health consequences of COPD patients and their spouses in Denmark-1998–2010. COPD J Chronic Obstr Pulm Dis. 2014;11:237–246.
   Web of Science ®Google Scholar
• Lisspers K, Larsson K, Johansson G, et al. Economic burden of COPD in a Swedish cohort: the ARCTIC study. Int J COPD. 2018;13:275–285. doi:10.2147/COPD.S149633
   Google Scholar
• Dalal AA, Patel J, D’Souza A, Farrelly E, Nagar S, Shah MJ. Impact of COPD exacerbation frequency on costs for a managed care population. Manag Care Spec Pharm. 2015;21(7):575–583.
   PubMed Web of Science ®Google Scholar
• Byng D, Lutter JI, Wacker ME, et al. Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET. Int J Chron Obstruct Pulmon Dis. 2019;14:1423–1439. doi:10.2147/COPD.S201899
   PubMed Web of Science ®Google Scholar
• Foo J, Landis SH, Maskell J, et al. Continuing to confront COPD international patient survey: economic impact of COPD in 12 countries. PLoS One. 2016;11(4):e0152618. doi:10.1371/journal.pone.0152618
   PubMed Web of Science ®Google Scholar
• Chen W, FitzGerald JM, Sin DD, Sadatsafavi M. Excess economic burden of comorbidities in COPD: a 15-year population-based study. Eur Respir J. 2017;50:1–10. doi:10.1183/13993003.00393-2017
   Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease - GOLD. Available from: https://goldcopd.org/. Accessed June 21, 2020.
   Google Scholar
• Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490. doi:10.2147/CLEP.S91125
   PubMed Web of Science ®Google Scholar
• Lange P, Tottenborg SS, Sorknaes AD, et al. Danish Register of chronic obstructive pulmonary disease. Clin Epidemiol. 2016;8:673–678. doi:10.2147/CLEP.S99489
   PubMed Web of Science ®Google Scholar
• Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data resource profile: the Danish national prescription registry. Int J Epidemiol. 2017;46(3):798–f. doi:10.1093/ije/dyw213
   PubMed Web of Science ®Google Scholar
• Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011;39(7 Suppl):103–105. doi:10.1177/1403494811405098
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sorensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549. doi:10.1007/s10654-014-9930-3
   PubMed Web of Science ®Google Scholar
• Stenton C. The MRC breathlessness scale. Occup Med (Chic Ill). 2008;58:226–227. doi:10.1093/occmed/kqm162
   PubMed Web of Science ®Google Scholar
• Blough DK, Ramsey SD. Using generalized linear models to assess medical care costs. Health Serv Outcomes Res Methodol. 2000;1(2):185–202. doi:10.1023/A:1012597123667
   Google Scholar
• ur Rehman A, Hassali MAA, Muhammad SA, Harun SN, Shah S, Abbas S. The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. Eur J Health Econ. 2020;21(2):181–194. doi:10.1007/s10198-019-01119-1
   PubMed Web of Science ®Google Scholar
• ur Rehman A, Hassali MAA, Muhammad SA, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res. 2020;20:661–672.
   PubMed Web of Science ®Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;26(15):439–460. doi:10.2147/COPD.S234942
   Web of Science ®Google Scholar
• Punekar YS, Shukla A, Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014;9:65–73. doi:10.2147/COPD.S54417
   PubMed Web of Science ®Google Scholar
• Ding B, Small M, Bergström G, Holmgren U. COPD symptom burden: impact on health care resource utilization, and work and activity impairment. Int J Chron Obstruct Pulmon Dis. 2017;21(12):677–689. doi:10.2147/COPD.S123896
   Web of Science ®Google Scholar
• Stephenson JJ, Wertz D, Gu T, Patel J, Dalal AA. Clinical and economic burden of dyspnea and other COPD symptoms in a managed care setting. Int J Chron Obstruct Pulmon Dis. 2017;4(12):1947–1959. doi:10.2147/COPD.S134618
   Web of Science ®Google Scholar
• Souliotis K, Kousoulakou H, Hillas G, Tzanakis N, Toumbis M, Vassilakopoulos T. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2017;12:1395–1400. doi:10.2147/COPD.S132825
   PubMed Web of Science ®Google Scholar
• Wallace AE, Kaila S, Bayer V, et al. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J Manag Care Spec Pharm. 2019;25(2):205–217. doi:10.18553/jmcp.2019.25.2.205
   PubMed Web of Science ®Google Scholar
• Liang L, Shang Y, Xie W, Shi J, Tong Z, Jalali MS. Trends in hospitalization expenditures for acute exacerbations of COPD in Beijing from 2009 to 2017. Int J Chron Obstruct Pulmon Dis. 2020;15:1165–1175. doi:10.2147/COPD.S243595
   PubMed Web of Science ®Google Scholar
• Wacker ME, Jörres RA, Schulz H, et al.; COSYCONET-Consortium. Direct and indirect costs of COPD and its comorbidities: results from the German COSYCONET study. Respir Med. 2016;111:39–46. doi:10.1016/j.rmed.2015.12.001
   PubMed Web of Science ®Google Scholar
• Stanford RH, Coutinho AD, Eaddy M, Yue B, Bogart M. Cost analysis of COPD exacerbations and cardiovascular events in SUMMIT. Am J Manag Care. 2019;25(11):e320–e325.
   PubMed Web of Science ®Google Scholar